Ionis Pharma

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ionis Pharma excels in Q4, eyes revenue growth and strategic expansion

Ionis Pharma's Q4 2022 performance reflects strong revenue growth, pipeline advancements, and strategic positioning for future success.
The company's focus on commercialization, R&D innovation, and financial discipline underscores its resilience and growth potential in the biopharmaceutical industry.
While facing challenges in operational costs and market dynamics, Ionis Pharma remains well-positioned to leverage opportunities in genetic medicines and revenue diversification.

Ionis Pharma reports strong Q1 earnings and outlines growth plans

Ionis Pharma's Q1 performance solid with revenue growth and strong cash position
Company's strengths lie in FDA approvals, positive study data, and pipeline progress
Challenges include rising expenses, competitive landscape, and pricing strategies
Opportunities seen in PV market, HAE program, and growth prospects in coming years

Ionis Pharma reports strong Q2 performance and prepares for launches

Ionis Pharma's Q2 2023 earnings call highlighted strong performance, with revenue growth, key milestones in pipeline advancements, and a solid financial position.
The company faces challenges in study readout timing, competitive landscape changes, and market competition but has opportunities for growth through successful enrollment and product launches.
Key strengths include successful collaborations, encouraging interim results for SPINRAZA, and preparations for upcoming product launches, positioning Ionis Pharma for future success.
Overall, Ionis Pharma remains focused on advancing its pipeline, meeting financial guidance, and leveraging opportunities for growth in the biopharmaceutical market.

Ionis Pharma reports strong Q3 performance and neurology pipeline advancements

Ionis Pharma's Q3 earnings call highlighted strong performance, strategic successes, and advancements in the neurology pipeline.
The company faces challenges in a competitive landscape but has strengths in partnerships, innovation, and pricing strategies.
Opportunities lie in upcoming data releases, potential treatment benefits, and market differentiation strategies.
Overall, Ionis Pharma remains focused on delivering value to patients and investors through its innovative therapeutics.

Ionis Pharma reports robust 2023 results and eyes growth opportunities

Ionis Pharma's strong financial performance in 2023 and projected revenue for 2024 reflect a promising outlook for the company's growth and commercialization efforts.
While facing challenges in patient eligibility and treatment optimization, Ionis Pharma's focus on pipeline advancement and strategic investments positions it well for future success.
The company's emphasis on neurological disease platforms, upcoming data readouts, and collaborations present significant opportunities for expansion and innovation.

Ionis Pharma reports robust Q1 performance and advances key treatments

Ionis Pharma's Q1 2024 performance reflects strong revenue growth and progress in key pipeline programs, positioning the company for future success and sustained positive cash flow.
With a focus on strategic investments, innovative treatments, and upcoming data presentations, Ionis demonstrates a commitment to driving growth and addressing unmet medical needs.
While facing challenges in managing expenses and securing regulatory approvals, Ionis Pharma remains well-positioned to capitalize on market opportunities and partnerships for continued development and commercial success.

Ionis Pharma reports solid Q2 earnings, eyes growth through innovation

Ionis Pharma's Q2 performance reflects steady revenue growth and positive feedback on recent launches and ongoing trials.
The company's strengths lie in its innovative therapies, strong clinical profile, and strategic focus on expanding the product portfolio.
Challenges include sustaining momentum in competitive markets and ensuring successful commercialization of upcoming products.
Opportunities exist in market expansion, new patient segments, partnerships for pipeline growth, and investments in next-gen technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Alkermes

Neurocrine Biosciences

ACADIA Pharma

Arrowhead Pharmaceuticals

BioMarin Pharmaceutical

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies that have shown strong historical revenue growth, improving fundamentals, and yet have not rallied.

ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?

Here's what it takes to justify the current valuation.

Is Ionis Pharmaceuticals a Buy?

CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that IONIS-PKK-LRx is being evaluated in an investigator-initiated Phase 2 clinical study to determine its effectiveness in reducing the...

Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC)...

Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.

Ionis' Alexander Disease Candidate Gets Orphan Drug Status

BOSTON and CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and...

Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

CARLSBAD, Calif., Sept. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ION373 for the treatment of people with Alexander...

Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Why Is Ionis Pharmaceuticals (IONS) Down 2.2% Since Last Earnings Report?

CARLSBAD, Calif., Sept. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema

Akcea Therapeutics

Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.

Ionis to Acquire Remaining Stake in Akcea, Stocks Rally

The biotech is being acquired by its largest shareholder.

Why Akcea Therapeutics Stock Skyrocketed Today

(Newsfile Corp. - August 31, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/62885_07ae7de5b4daaa4c_001full.jpgTo: All Persons or Entities who purchased Akc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Akcea Therapeutics, Inc. to Ionis Pharmaceuticals, Inc.

Akcea Therapeutics Inc. (NASDAQ: AKCA) stock jumped on Monday after it was announced that Ionis Pharmaceuticals Inc.

What Akcea Shareholders Get in the Ionis Buyout

Akcea Therapeutics Inc (NASDAQ: AKCA) shares were rallying strongly Monday following a buyout deal.

Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining Stake

BOSTON and CARLSBAD, Calif., Aug. 29, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020

Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020

CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals to hold cardio-renal franchise webcast

BOSTON and CARLSBAD, Calif., Aug. 24, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020

BOSTON and CARLSBAD, Calif., Aug. 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.

Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q2 2020 Results - Earnings Call Transcript

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 17.86% and -3.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q2 results.

News for Ionis Pharma Stock (IONS)